VAM
GLMD icon

Visium Asset Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Visium Asset Management’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-860
Closed -$1.33M – 1101
2014
Q3 		$1.33M Hold
860
– – 0.02% 541
2014
Q2 		$1.51M Hold
860
– – 0.02% 460
2014
Q1 		$1.78M Buy
+860
New +$2.01M 0.03% 394

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return

Visium Asset Management's GLMD Position: Q4 2014 in Review

Visium Asset Management sold out of Galmed Pharmaceuticals (GLMD) in Q4 2014, closing a stake of 860 shares — an estimated $1.33M sold.

Visium Asset Management first reported a position in GLMD in Q1 2014 and held it in 3 quarters. The position peaked at $1.78M in Q1 2014. 16 funds tracked by Wall St. Rank hold GLMD as of Q4 2014.

  • Visium Asset Management reported no remaining Galmed Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Visium Asset Management sold 860 Galmed Pharmaceuticals shares in Q4 2014, an estimated $1.33M.
  • Visium Asset Management first reported a position in Galmed Pharmaceuticals in Q1 2014 and held it in 3 quarters.
  • Visium Asset Management's Galmed Pharmaceuticals position peaked at $1.78M in Q1 2014.
  • 16 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2014.

Based on Visium Asset Management's 13F filing for Q4 2014, filed 13 Feb 2015.